| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
ORIGINAL ARTICLE |
1 Department of Paediatric Haematology/Oncology, VU University Medical Centre, De Boelelaan 1117, PO Box 7057, 1007 MB, Amsterdam, The Netherlands
2 Department of Medical Oncology, VU University Medical Centre
3 Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology Hellas, 711 10 Herakleion, Greece
4 MRC Childhood Leukaemia Working Party, Glasgow G3 8SJ, UK
5 AML-BFM Study Group, Münster D-48129, Germany
Correspondence to:
Dr G J L Kaspers
Department of Paediatric Haematology/Oncology, VU University Medical Centre, De Boelelaan 1117, PO Box 7057, 1007 MB, Amsterdam, The Netherlands; GJL.Kaspers{at}vumc.nl
Background: Deoxycytidine kinase (dCK) is responsible for the activation of several clinically important deoxynucleoside analogues used for the treatment of haematological and solid malignancies.
Aim: To measure dCK expression in tumour cells from different origins.
Method: A rabbit antihuman dCK antibody was used for the immunocytochemical detection of dCK expression in three leukaemic cell lines (HL60, U937, and CCRF-CEM) and 97 patient samples (paediatric acute myeloid leukaemia (AML) and lymphoid leukaemia (ALL), retinoblastoma, paediatric brain tumours, and adult non-small cell lung cancer (NSCLC)).
Results: CCRF-CEM, U937, and HL60 cells stained positively for dCK and the degree of expression correlated with dCK activity. dCK expression varied between tumour types and between individual patients within one tumour type. dCK was located predominantly in the cytoplasm. The staining intensity was scored as negative (0), low (1+), intermediate (2+), or high (3+). Expression of dCK was high in AML blasts. In contrast, brain tumour samples expressed low amounts of dCK. dCK staining ranged from low (1+) to high (3+) in ALL blasts, retinoblastoma, and NSCLC tissue samples. Staining was consistent (interobserver variability, 88%; 
= 0.83) and specific. Western blotting detected the dCK protein appropriately at 30 kDa, without additional bands.
Conclusions: Immunocytochemistry is an effective and reliable method for determining the expression of dCK in patient samples and requires little tumour material. This method enables large scale screening of dCK expression in tumour samples.
Abbreviations: ALL, acute lymphoid leukaemia; AML, acute myeloid leukaemia; ara-C, cytarabine; dCK, deoxycytidine kinase; NSCLC, non-small cell lung cancer; PBS, phosphate buffered saline
Keywords: deoxycytidine kinase; immunocytochemistry; childhood acute leukaemia; solid tumours; deoxynucleoside analogues
This article has been cited by other articles:
|
|
 |
|
  L. Johnson, R. Lai, C. Santos, L. Dabbagh, and J. Mackey Unexpected Immunohistochemical Localization of Deoxycytidine Kinase. Clin. Cancer Res., November 15, 2006; 12(22): 6863 - 6863. [Full Text] [PDF]
|
|
|
|
|
|
V. Sebastiani, F. Ricci, B. Rubio-Viquiera, P. Kulesza, C. J. Yeo, M. Hidalgo, A. Klein, D. Laheru, and C. A. Iacobuzio-Donahue Immunohistochemical and Genetic Evaluation of Deoxycytidine Kinase in Pancreatic Cancer: Relationship to Molecular Mechanisms of Gemcitabine Resistance and Survival Clin. Cancer Res., April 15, 2006; 12(8): 2492 - 2497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Bergman, P. P. Eijk, V. W.T. Ruiz van Haperen, K. Smid, G. Veerman, I. Hubeek, P. van den IJssel, B. Ylstra, and G. J. Peters In vivo Induction of Resistance to Gemcitabine Results in Increased Expression of Ribonucleotide Reductase Subunit M1 as the Major Determinant Cancer Res., October 15, 2005; 65(20): 9510 - 9516. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
| Journal of Clinical Pathology | Molecular Pathology |
